Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Protocol GA29144

NCT02403323 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02403323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02403323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Protocol GA29144
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Terminated
Start date
June 8, 2015
Completion date
October 9, 2023
Enrollment
790 (actual)
Sites
287

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease